KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.

Claudine Isaacs, Rita Nanda, Christina Yau, A Jo Chien, Dawn L Hershman, Erica M Stringer-Reasor, Anne M Wallace, Alexandra Thomas, Christos Vaklavas, Amy S Clark, Laura C Kennedy, Amy Sanford, Judy C Boughey, Kathy S Albain, Lajos Pusztai, Kevin M Kalinsky, Heather Beckwith, Nicole O Williams, Hyo S Han, Carla Falkson, Mili Arora, Anthony D Elias, Paula R Pohlmann, Mariya Rozenblit, Natalie Marshall, Yunn-Yi Chen, Meghna S Trivedi, Julia E McGuinness, Frederick M Howard, Nan Chen, Katia Khoury, Rachael B Lancaster, Kay T Yeung, Emily Douglas, Mei Wei, Candace Mainor, Barbara LeStage, Amy L Delson, Adam L Asare, Lamorna Brown-Swigart, Gillian L Hirst, Jeffrey B Matthews, Jane Perlmutter, W Fraser Symmans, Douglas Yee, Nola M Hylton, Laura J van 't Veer, Hope S Rugo, Angela M DeMichele, Donald A Berry, Laura J Esserman

JAMA Oncol e262576

PMID42530945
PMCIDPMC13425239
DOI10.1001/jamaoncol.2026.2576
发表日期2026-07-30
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

IMPORTANCE: Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. OBJECTIVE: To evaluate the combination of anti-programmed cell death 1 protein (PD-1) cemiplimab and anti-lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2-negative early-stage, high-risk breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) is an ongoing randomized clinical platform trial being conducted at multiple US clinical sites including patients with early-stage (II or III) ERBB2-negative, high-risk breast cancer. Participants, continuously enrolled since 2010, were adaptively randomized from February 2, 2020, to December 9, 2021, to one of several experimental neoadjuvant therapies or control groups based on receptor subtypes defined by hormone receptor (HR), ERBB2 status, and MammaPrint (Agendia Inc) molecular risk, categorized as high (MP1) or ultrahigh (MP2). Data were analyzed from January 1, 2022, to August 5, 2025. INTERVENTIONS: Both groups received weekly paclitaxel for 12 weeks, then doxorubicin and cyclophosphamide followed by surgery; concomitant with paclitaxel, the intervention group also received 4 doses of cemiplimab and fianlimab (PCF) every 3 weeks. MAIN OUTCOMES AND MEASURES: Pathologic complete response (pCR). Treatments graduated when they achieved 85% bayesian probability of success in a subtype-specific phase 3 trial. Pathway-specific biomarkers were assessed for response prediction. RESULTS: A total of 78 participants (mean [SD] age, 47 [39-54] years) were randomized to the intervention group, with 350 participants (mean [SD] age, 48 [39-57] years) randomized to the historical control population. PCF graduated in all clinical signatures, with pCR rates vs control of 44% (95% CI, 34%-53%) vs 21% (95% CI, 17%-25%) in all ERBB2, 53% (95% CI, 39%-67%) vs 29% (95% CI, 22%-36%) in triple-negative, and 36% (95% CI, 23%-49%) vs 14% (95% CI, 9%-19%) in HR-positive and ERBB2-negative disease. Among the total participants, 16 (21%) experienced adrenal insufficiency, including hypophysitis (11% grade 3 or 4), mostly occurring after immunotherapy completion. PCF was found to be highly effective in the subset of patients with immune signature positive status (ImPrint positive). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the combination of PD-1 and anti-LAG-3 inhibition with standard NAC was effective in early-stage ERBB2-negative breast cancer, particularly in patients displaying a positive ImPrint immune signature. These results warrant further definitive trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01042379.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。